Get the Stockscreener App
1.80
3.23%
-0.06
Pre-market:
1.80
Biovie Inc stock is traded at $1.80, with a volume of 400.38K.
It is down -3.23% in the last 24 hours and down -18.55% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.86
Open:
$1.88
24h Volume:
400.38K
Relative Volume:
0.27
Market Cap:
$31.98M
Revenue:
-
Net Income/Loss:
$-25.56M
P/E Ratio:
-0.3462
EPS:
-5.2
Net Cash Flow:
$-19.35M
1W Performance:
+3.45%
1M Performance:
-18.55%
6M Performance:
-27.42%
1Y Performance:
-84.62%
1-Day Range:
$1.80
$1.9093
1-Week Range:
$1.6825
$2.04
52-Week Range:
$1.0404
$33.10
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.80 | 31.98M | 0 | -25.56M | -19.35M | -5.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
A Guide To The Risks Of Investing In BioVie Inc (BIVI) - Knox Daily
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Healthy Upside Potential: BioVie Inc (BIVI) - SETE News
Now Is The Time To Build A Position In BioVie Inc (NASDAQ:BIVI) - Marketing Sentinel
BioVie Inc (BIVI) Stock: Navigating Drops and Gains - The InvestChronicle
BioVie Inc (BIVI)’s stock rises to 1.74 per share - US Post News
Stock Market Recap: BioVie Inc (BIVI) Concludes at 1.60, a -3.03 Surge/Decline - The Dwinnex
IMMINENT BIVI DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds BioVie Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out | NDAQ:BIVI | Press Release - Stockhouse Publishing
2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events - Big News Network
2025-01-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect - Stockhouse Publishing
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
BIOVIE, INC. CLASS ACTION ALERT: Biovie, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Been Filed In The United States District Court for The District of Nevada Against Biovie, Inc. - AccessWire
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
BioVie Leaders Sued for Stock Slips on Clinical Trial Misconduct - Bloomberg Law
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out - AccessWire
Certain Common Stock of BioVie Inc. are subject to a Lock-Up Agreement Ending on 24-DEC-2024. - Marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect - AccessWire
BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-15 | BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIVI | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Ascites Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
SEC goes after David Banister and The Market Analysts Group - FX News Group
SEC Sues Investment Advisor Over $1.4 Million Pump-and-Dump Scheme Involving BioVie Stock - USA Herald
SEC Accuses Investment Advisor of $1.4M Pump-and-Dump Scheme Involving BioVie Inc. - USA Herald
BioVie Sued By Block & Leviton LLP for Securities Law Violations - GlobeNewswire
Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference - Marketscreener.com
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference - The Manila Times
BioVie to Present Design of Planned Phase 2 Study of - GlobeNewswire
BioVie's Long COVID Drug Trial Gets Pentagon Backing; Phase 2 Study to Include 200 Patients | BIVI Stock News - StockTitan
BioVie shareholders approve board nominees and equity plan expansion By Investing.com - Investing.com Canada
BioVie shareholders approve board nominees and equity plan expansion - Investing.com India
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded - GlobeNewswire
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded - The Manila Times
BioVie Raises Capital Through Direct Stock Offering - MSN
BioVie Inc. Announces Closing of Registered Direct Offering - GlobeNewswire
BioVie Raises $3.24 Million in Direct Offering - TipRanks
BioVie sets price for $3.2 million stock offering By Investing.com - Investing.com Australia
BioVie prices stock offering at $2.83 per share By Investing.com - Investing.com Canada
BIVIBioVie, Inc. Latest Stock News & Market Updates - StockTitan
BioVie prices stock offering at $2.83 per share - Investing.com
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
BioVie sets price for $3.2 million stock offering - Investing.com India
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):